



BIO-GENE
TECHNOLOGY
LTD

ASX: BGT

**2019 AGM
CEO Update**

Richard Jagger
26 November 2019

Disclaimer

This presentation has been prepared by Bio-Gene Technology Limited (ASX:BGT) (the Company). This presentation is not, and should not be considered, an offer or invitation to apply for or purchase securities in the Company or as a recommendation or inducement to make an offer or invitation in respect of securities in the Company. No agreement to subscribe for securities will be entered into on the basis of this presentation or any information contained in this presentation.

This presentation is not a prospectus, product disclosure document or other offering document under Australian law or under the law of another jurisdiction. This presentation is provided for general information purposes only and is selective, does not purport to contain all relevant information and has not been independently verified.

Neither the Company nor its advisors have any responsibility or obligation to inform any recipient of any matter arising or coming to their notice after the date of this presentation, which may affect any matter referred to in the presentation. The Company releases material information as announcements to the ASX (ASX:BGT). Recipients seeking further information in respect of the Company should review the Company's announcements as released to ASX from time to time.

Nothing in this presentation constitutes investment, legal, tax, accounting or other advice. The recipient should consider its own financial situation, objectives and needs and conduct its own independent investigation and assessment, including obtaining investment, legal, tax, accounting or other advice as it considers necessary or appropriate.

The distribution of this presentation (including electronic copies) outside Australia may be restricted by law and persons who come into possession of this presentation outside Australia should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.

This presentation may contain statements relating to intentions, future acts and events (Forward Looking Statements). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed. No representation, warranty or guarantee, express or implied, is given that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable.


No financial information (unless also contained in financial reports released to ASX), estimates or projections contained in this presentation or as derived from such financial information, estimates or projections can be relied upon as a promise or representation as to any present or future matter.

To the maximum extent permitted by law, neither the Company nor any of its associates, directors, officers, employees, advisors or representatives make any representation or provide any warranty, express or implied, as to the accuracy, reliability or completeness of the information contained in this presentation or any subsequent information provided to the recipient including, but not limited to, any financial projections, estimates or other historical information.

Investment Highlights

Bio-Gene's technology addresses the needs of a large and growing global problem of pest resistance

Bio-Gene has a compelling value proposition



Data shows compounds are highly effective



Low toxicity to beneficial insects




>5,000x less impactful on bee populations



Novel Mode of Action



Strong IP portfolio



Scalable technology



Significant global opportunity across four verticals



Third-party validation of technology

2019 Year in Review

Significant progress has been made on improving the value proposition of both Qcide™ & Flavocide™

Additional safety trials

- Completed study on beneficial insects showing no adverse effects
- Identified & engaged a consultant to review toxicology profile and studies

Anopheles Mosquito studies

- Purdue University reviewing Flavocide and Qcide on malaria-carrying mosquito

Intellectual Property

- Submitted two new international patents
- Developed significant intellectual property relating to manufacturing

Commercialisation Strategy

- Exclusive partnership with **BASF**, **GRDC**, and **DAF** to develop Flavocide for use in Stored Grain Pest control in Australia
- Currently six Material Transfer Agreements in place globally with more underway. Testing covering both Qcide & Flavocide across all four verticals.

Qcide-specific progress in FY19

Significant interest exists in Qcide from potential partners

Qcide progress

- Significant increase in investment in Qcide programs (~47% budget)
- James Cook University collaboration focusing on improved oil extraction, tree cloning program to improve yield consistency
- Additional harvesting programs to test extraction technique
- Significant IP around these techniques, with potential to develop more
- Completed Acute toxicity testing
- Strong interest in our natural product from global companies has resulted in testing of our product over a number of market opportunities
- Demonstrated synergistic effects of adding Qcide to sub-label rates of other insecticides (Purdue studies)
- Commenced Qcide studies on major mosquito vectors at Purdue University (partially delayed due to restricted access to mosquito quantities)
- Developed new combination formulations with Qcide for knockdown sprays and personal repellents, enabling testing to begin on resistant flies to demonstrate effectiveness of novel Mode of Action

Flavocide-specific progress in FY19

Substantial progress on Flavocide including manufacturing

Flavocide progress

Improved manufacturing

- Completed CSIRO synthesis development, resulting in reduced costs, and waste, and increased yield
- Scale-up program with Boron Molecular, aimed at improving on CSIRO methodology through larger production quantities
- Created significant IP relating to Flavocide manufacture
- Field studies on a range of key crop pests
- Additional lab studies on crop pests, aimed at completing data package
- Positive results from 28-day oral and dermal toxicity studies
- Efficacy testing Flavocide 6-month residual application; stored grain pests
- Signed BASF and GRDC to our stored grain pest application with financial and resource commitments

Mosquito trials

- Approaching completion of Anopheles (malaria carrying mosquito) studies at Purdue to round out vector control application proposals

Flavocide Testing



Prof. Catherine Hill
Purdue University
BGT Scientific Advisory
Board Member

- Purdue university, department of entomology
- Showalter faculty scholar
- President's fellow for the life sciences
- Authority in new insecticide development & novel chemistry



Bio-Gene has four major target verticals

Focus remains on providing new solutions across four key target verticals



Crop Protection



Grain Storage



Public Health



Consumer Products

Total Addressable market of US\$25.1bn

Australian stored grain pest control partnership trial

All key representatives aligned on stored grain partnership trial



Funding, market access & regulatory expertise

BASF world's largest chemical company and leading developer of new chemistry to the agriculture sector



Research

Department of Agriculture & Fisheries, Queensland Government (**DAF**), recognised experts in field of resistant stored grain pests



Funding & industry validation

Grains Research & Development Corporation (**GRDC**) Australia's national grains RD&E body, committed to developing new technology



Technology, funding & expertise

Bio-Gene provides patented, nature identical molecule Flavocide™ to address the issue of resistant stored grain pests

There exists a pipeline of further potential partnerships

Currently six 'Material Transfer Agreements' signed to explore opportunities across four key verticals globally

Bio-Gene aims to develop further significant partnerships from existing and future MTA's



Crop Protection



Grain Storage



Public Health



Consumer Products

Looking ahead

Focus is on advancing the commercialisation strategy and delivering on key milestones

Advance MTA's to partnership stage

- Progress additional companies / organisations to formal agreements
- Sign new MTA's with additional companies

Progressing trial data relating to vector control to enable Bio-Gene to leverage conversations with key stakeholders

- Bio-Gene has identified the data required to progress trials
- Completing the dataset
- Progressing conversations with key stakeholders

Complete current studies on Grain Storage pests, and begin BASF program

- Assess residual efficacy data on 9 month samples of grain
- Commence next stage Stored Grain study at DAF

Continue to improve production capability

- Pilot plant trials underway at Boron Molecular to scale-up production of Flavocide and identify further process improvements and cost reductions



BIO-GENE TECHNOLOGY LTD

Richard Jagger
CEO

(03) 9068 1062
richardj@bio-gene.com.au

Roger McPherson
CFO, Co. Sec.

(03) 9068 1062
rogerm@bio-gene.com.au